January 18, 2010

To Whom It May Concern

KYORIN Co., Ltd.
5, Kanda Surugadai 2-chome,
Chiyoda-ku, Tokyo
Securities Code: 4569; TSE 1st Section

MARKETING APPROVAL FOR "MUCODYNE® DS50%"

KYORIN Pharmaceutical Co., Ltd. (Headquarter: Tokyo, President: Keiji Hirai), a subsidiary of KYORIN Co., Ltd. announced today that the Ministry of Health, Labour and Welfare approved "MUCODYNE® DS50%" (INN: L-Carbocisteine), Mucoregulating drug, on January 15, 2010.

Kyorin Pharmaceutical Co., Ltd. first marketed MUCODYNE® Tablets (for adults) in January 1981. Later, Kyorin Pharmaceutical Co., Ltd. released MUCODYNE® Fine Granules 50% (for adults), MUCODYNE® Syrup 5% (for children), MUCODYNE® Tablets 500 mg (for adults) and MUCODYNE® DS（Dry Syrup）33.3% (for both adults and children) as additional formulations of MUCODYNE® to meet the needs of patients and medical workers. Kyorin Pharmaceutical Co., Ltd. has also obtained indications for drainage in chronic sinusitis and drainage in otitis media with effusion[*1] after initial marketing in Japan.

MUCODYNE® DS 50%, for which Kyorin Pharmaceutical Co., Ltd. gained manufacturing and marketing approval on the date given above, is a formulation developed by improving MUCODYNE® DS 33.3%, which is already on the market. This formulation is expected to not only reduce patient dosage but also attenuate the burden on medical workers by simplifying prescription volume conversion at dispensing points.

Kyorin Pharmaceutical Co., Ltd. will continue to step up its contribution to the treatment of respiratory, otolaryngological and other diseases with this latest acquisition of manufacturing and marketing approval for MUCODYNE® DS 50%, in addition to continuing to provide the latest information on the MUCODYNE® , including findings through the PEACE Study[*2].

*1 Kyorin Pharmaceutical Co., Ltd. has obtained indications for exudative otitis media for MUCODYNE® Syrup and MUCODYNE® DS only.

*2「Preventive Effect on Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) with Carbocisteine 1500mg/day」

For Further information, Contact:
KYORIN Co., Ltd.
Management Planning Department
Telephone: +81-3-3293-3414
Fax: +81-3-3293-3454

＜Product Profile for MUCODYNE® DS 50%＞

PRODUCT NAME	MUCODYNE® DS50%
INN	L-Carbocisteine
INDICATIONS	**For adults** Expectoration for the following diseases: Upper respiratory inflammation (pharyngitis, Laryngitis), acute bronchitis, bronchial asthma, chronic bronchitis, bronchiectasis and pulmonary tuberculosis. Drainage in chronic sinusitis. **For children** Expectoration for the following diseases: Upper respiratory inflammation (pharyngitis, laryngitis), acute bronchitis, bronchial asthma, chronic bronchitis, bronchiectasis and pulmonary tuberculosis. Drainage in chronic sinusitis. Drainage in otitis media with effusion.
DOSAGE AND ADMINISTRATION	**For adults** For oral use, the usual dose for adults is 500 mg of L-carbocisteine (1.0g of MUCODYNE® DS50%) three times daily. MUCODYNE® DS50% should be suspended immediately before use. The dose may be adjusted according to age and symptoms. **For children** For oral use, the usual dose for children is 10 mg/kg of L-carbocisteine (0.02g/kg of MUCODYNE® DS50%) three times daily. MUCODYNE® DS50% should be suspended immediately before use. The dose may be adjusted according to age and symptoms.
NHI PRICE	Not listed
PACKAGING	Boxes of 120 packets (1.0g×120 packets) Bottles of 100 g, and bottles of 500 g.

Underlined sections correspond to changes from MUCODYNE® DS 33.3%.

Reference: Indicated use and marketing launch for each MUCODYNE formulation

Formulations	For adults	For children	Marketing launch
MUCODYNE® Tablets 250mg	○	－	Date of initial marketing in Japan: July 2001 ＊ Marketed in January 1981 under the name of MUCODYNE® Tablets
MUCODYNE® Tablets 500mg	○	－	Date of initial marketing in Japan: October 1996
MUCODYNE® Fine Granules 50%	○	－	Date of initial marketing in Japan: November 1987
MUCODYNE® Syrup 5%	－	○	Date of initial marketing in Japan: October 1987
MUCODYNE® DS 33.3%	○	○	Date of initial marketing in Japan: October 2001 ＊ Scheduled to be discontinued after a fixed period following the release of MUCODYNE® DS 50%
MUCODYNE® DS 50%	○	○	Date of initial marketing in Japan: Not yet determined